‘C-Tri’ has first acquired the oral treatment for spinocerebellar degeneration in Korea

The pharmaceutical company specializing in the non-natureamino acid mass production technology and peptide,‘C-Tri’ (CEO Wan-ju Kim), has acquired the domestic approval to manufacture and sell ‘Citrelin ODT 5mg’ on the last 6^th for the first time.

On every treatment for spinocerebellar degeneration in Korea, patients either had to rely on allopathic treatments due to lacking proper treatments o...